Home » Newsletters » BioWorld Science

BioWorld Science

May 16, 2001

View Archived Issues

NIH licensing opportunity: detection and quantification of CR1 in human milk using ELISA

NIH licensing opportunity: identification of new small bacterial RNAs

Durect acquires Southern BioSystems

Rituximab filed in E.U., approved in U.S. for expanded indications

FDA advisory committee to review NDA for first-in-class antidiabetic therapy

First combination hepatitis A & B vaccine approved by FDA

Centaur's CPI-1189 shows efficacy in phase IIa trials in patients with dementia

Crucell and UMC Utrecht enter alliance for type 2 diabetes therapeutics

Phase II liver cancer trial of Zadaxin/TACE announced

Manzamine alkaloids from deep-sea sponge show potent antiinfective activity

Anticonvulsant agents reduce trigeminal nerve-induced neurovascular reflexes

Progenics reacquires rights to cancer vaccines; phase III trial in melanoma begins

First-quarter 2001 highlights and product update presented by NPS

AltaRex presents encouraging results from phase I BrevaRex MAb trial

Long-term safety and efficacy of adalimumab demonstrated in active RA

Company Profile: Hormos Medical

NDA filed in Hong Kong for NexMed's ED treatment

Humanized antibody safe and effective in phase I/II studies in RA patients

Several ARVO presentations cover preclinical and early clinical profile of AL-6598

AGI Dermatics reports promising results with skin cancer prevention drug

Company Profile: OPi

Cor patents new series of factor Xa inhibitors with high potency and selectivity

New indole-based sPLA2 inhibitors in development at Lilly

AstraZeneca identifies quinazoline derivatives as inhibitors of aurora2 kinase

Preparation and use of calcium channel antagonist series described by Ortho-McNeil

Small molecules from Genentech inhibit interaction between alpha4 integrins and their ligands

Meiji Seika's new phosphonic acid derivatives particularly useful in thrombotic disorders